Generic tenofovir tablet put to the test in healthy volunteers
NCT ID NCT07558967
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1 trial compared a generic tenofovir disoproxil fumarate tablet to the brand-name Viread in 47 healthy Chinese adults. Participants took a single 300 mg dose under fasting or fed conditions to see if the generic version is absorbed similarly. The study focused on blood levels and safety, not on treating any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tenofovir disoproxil fumarate (an antiviral drug used for HIV and hepatitis B)
- What this could lead to
- If successful, this could show that the generic version is equivalent to the brand-name drug, potentially offering a lower-cost option for patients.
- What could go wrong
- This is a small, early-phase study in healthy people, not patients. It only checks how the drug is absorbed and does not test effectiveness against any disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
General Hospital of Shenyang Military Region
Shenyang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test